At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 52 enrolled
Drug / intervention
89Zr-Trastuzumab Human Dosimetry and Safety +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab
In Brief
A Early Phase 1 clinical trial evaluating 89Zr-Trastuzumab Human Dosimetry and Safety and HER2 Positive Lesion Detection and Safety for Breast Cancer. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Early Ph 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedFeb 2014
Primary CompletionDec 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartFeb 1, 2014
Primary CompletionDec 31, 2017
Study CompletionFeb 13, 2018
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 12.4 years ago
Interventions
89Zr-Trastuzumab Human Dosimetry and Safetydrug
PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
HER2 Positive Lesion Detection and Safetydrug
Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging